Amplia Therapeutics Limited (ASX:ATX)

Bally's Cash Flow Statement

Financials in millions AUD. Fiscal year is April - March.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022	Mar 31, 2021
Net Income	-6.57	-4.5	-6.24	-3.64	-2.28
Depreciation & Amortization	0.09	0.09	0.07	0	0
Stock-Based Compensation	0.08	0.09	0.21	0.06	0.35
Other Operating Activities	0.06	0	0	-0	0
Change in Accounts Receivable	-0.67	-2.04	0.68	-0.83	-1.02
Change in Accounts Payable	0.13	1.25	-0.01	0	0.03
Operating Cash Flow	-6.89	-5.13	-5.29	-4.4	-2.92
Capital Expenditures	-0	-0	-0.02	-0.01	-0.01
Other Investing Activities	-	-	-0.04	-0.01	-
Investing Cash Flow	-0	-0	-0.06	-0.03	-0.01
Long-Term Debt Issued	-	1.47	-	2.1	-
Long-Term Debt Repaid	-1.55	-2.18	-0.06	-	-
Net Debt Issued (Repaid)	-1.55	-0.71	-0.06	2.1	-
Issuance of Common Stock	17.28	0	0.02	16.27	4.06
Other Financing Activities	-1.41	-0.06	-0.04	-1.18	-0.4
Financing Cash Flow	14.32	-0.77	-0.08	17.19	3.66
Foreign Exchange Rate Adjustments	0.05	0.03	0.08	-0	-0
Net Cash Flow	7.48	-5.87	-5.35	12.76	0.74
Free Cash Flow	-6.89	-5.13	-5.31	-4.42	-2.92
Free Cash Flow Margin	-182.04%	-115.20%	-446.19%	-222.68%	-190.52%
Free Cash Flow Per Share	-0.02	-0.03	-0.03	-0.03	-0.03
Cash Interest Paid	0.08	0.06	0.04	-	-
Cash Income Tax Paid	-3.18	-2.41	-1.84	-1.14	-0.57
Levered Free Cash Flow	-4.77	-3.59	-2.99	-3.07	-2.1
Unlevered Free Cash Flow	-4.74	-3.54	-2.95	-3.07	-2.1
Change in Net Working Capital	0.65	0.85	-0.71	0.85	0.99

Updated Nov 27, 2024. Source: S&P Global Market Intelligence. Standard template. Financial Sources.